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ABSTRACT
Background: Guideline directed medical therapy (GDMT) is the cornerstone of reducing
mortality and morbidity in patients with heart failure with reduced ejection fraction (HFrEF);
however, uniform prescribing remains low. There is potential for multidisciplinary care teams,
including pharmacists, to improve GDMT use in outpatient care for patients with HFrEF.
Investigation is needed to understand the impact of pharmacists in outpatient HFrEF care on
GDMT prescribing.
Objectives: To examine the impact of integrating a pharmacist into an outpatient cardiology
setting on GDMT prescription rates during HFrEF-related clinic visits.
Methods: This retrospective chart review study examined cardiology clinic visits (HF clinic,
“general cardiology” clinic, and pharmacist-only visits) before and after integration of
pharmacists in the clinic. Visits were included for HFrEF patients (EF < 40%) from January 1,
2018 to July 1, 2019.
Results: Pharmacist visits had a significantly higher rate of GDMT compliance and significantly
lower rate of harmful medication prescriptions than general cardiology visits (p<.05). There was
a significant difference in GDMT compliance between the HF clinic and the general cardiology
clinic after the integration of pharmacists (p<.05), but no significant difference prior.
Conclusions: Integrating a pharmacist in the outpatient HFrEF care team can improve GDMT
prescribing. Efforts should focus on workflow to optimize the role of the pharmacist in the clinic,
and improving quality of data entry, such as standardized documentation of GDMT exceptions.

Key Words: heart failure, medication, ambulatory care, outpatient, chart review, medication,
prescription
Abbreviations
GDMT

Guideline directed medical therapy

HFrEF

Heart failure with reduced ejection fraction

HF

Heart failure

EF

Ejection fraction

ACEI

Angiotensin-converting enzyme inhibitors

ARB

Angiotensin II receptor blockers
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ARNI

Angiotensin receptor-neprilysin inhibitors

MRA

Mineralocorticoid receptor antagonist

INTRODUCTION
Millions of people worldwide are affected by heart disease, and it is the leading cause of
death in the United States.[1] Heart failure (HF) affects over 6 million people in the United
States age 20 and older, and this number is expected to increase to over 8 million people age 18
and older by 2030.[2] Evidence demonstrates that guideline directed medical therapy (GDMT)
is the cornerstone of reducing mortality and morbidity in patients with HFrEF.[3] However, gaps
in physicians’ use and appropriate titration of medications exist.[4] Prescribing GDMT for
patients with HFrEF is a complex decision-making process that includes multiple providers,
communication with patients, and assessment and adjustment of treatment and therapy for the
duration of the patients’ lives. Patient safety is a key concern, as patients have contraindications
and intolerances to medications (herein referred to as exceptions to GDMT) that must be
evaluated before adjusting doses. Optimization of GDMT significantly improves health
outcomes and quality of life for people with HFrEF, and the process is highly personalized due
to complexity of the therapy and the need to navigate exceptions.[5]
Multidisciplinary interventions and approaches to the treatment of heart failure have the
potential to improve patient outcomes.[6] Due to the complexity of GDMT, pharmacists are
particularly helpful in guiding decision making for titrating medication as well as patient
education.[7] Findings from a small pilot study following 36 patients in an outpatient setting
suggested that there is potential for a pharmacist-managed medication titration clinic to enhance
titration, improve left ventricular EF, and enhance clinical and economic outcomes.[8] In order
to examine the overall impact of integrating pharmacists in a HF clinic on adherence to GDMT
prescription, we conducted a retrospective chart review to compare the number of patients who
were on GDMT medications before and after the integration of the pharmacists into the clinic.
GDMT classes of medications include: (angiotensin-converting enzyme inhibitors (ACEI),
angiotensin II receptor blockers (ARB), or angiotensin receptor-neprilysin inhibitors (ARNI),
beta-blockers, and mineralocorticoid receptor antagonist (MRA). We evaluated the impact of a
pharmacist position integrated in an outpatient HF clinic on GDMT adherence rates for patients
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with HFrEF by comparing 1) percentage of patients on GDMT across a cardiology outpatient
setting and 2) percentage of patients on harmful medications across a cardiology outpatient
setting, before and after integration of pharmacists into the HF clinic.

METHODS
A retrospective observational study was conducted across 14 cardiology outpatient
locations in one healthcare system. A HF clinic operates at two of the 14 locations, and at one of
these locations, pharmacist visits were integrated into patient care. At all other locations,
outpatient cardiology visits were considered “general cardiology” clinic visits. Visits were
included for patients who met the following criteria: 18 years or older, Medicare or Medicare
replacement as primary insurance, low ejection fraction (EF < 40%), and one or more clinic
visits in a target cardiology clinic during January 1, 2018 to July 1, 2019. Visits were excluded
for patients who did not meet inclusion criteria or were receiving hospice or palliative care.
Approval for this study was obtained from the hospital’s Institutional Review Board prior to data
collection.

Integration of Pharmacists
The HF clinic integrated pharmacists in October 2018 and beginning in November 2018.
A pharmacist was included as part of the HF clinic infrastructure, dedicating 16 hours per week
in the clinic. The pharmacist had individual appointments with patients, and by nature of being in
the HF clinic, were also available for consults with other providers. Pharmacist visits were
focused on patient education about medications and could occur prior or subsequent to visits
with a nurse practitioner (NP) in the HF clinic. Pharmacists would consult with NPs regarding
medication changes, however there was no standardized documentation of these interactions.
The pharmacist visits were documented and billed separately in the medical record. Outpatient
visits in the HF clinic were typically scheduled for 30 minutes with the NP or pharmacist.
General cardiology outpatient visits were typically scheduled for 15 minutes with the physicians
and 20 minutes with NPs. The primary outcome of interest was GDMT compliance which
included prescriptions for the following three medication categories: 1) ACEI, ARB, or ARNI, 2)
beta-blocker, and 3) mineralocorticoid receptor antagonist (MRA).
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Data Collection
Data extracted from the electronic health record included demographics, co-morbidities,
provider, race, date of encounter, encounter type, medications, clinic, and medical diagnoses.
Patient encounters subsequent to EF measured by echocardiogram with results greater than or
equal to 40% were omitted. Additionally, patients with angioedema were excluded from the
sample. Four exceptions to GDMT prescribing were considered, patients with: 1) heart rates
below 60 bpm, 2) systolic blood pressure below 90 mmHg, 3) 2 or more potassium values above
5mmol/L, and 4) 2 or more creatinine values above 2.5 mg/dL. When any of these conditions
were present in the 30 days prior to the patient encounter, the visit was excluded from analyses.
After these exclusions, the sample contained 2013 visits for 754 unique patients. Medication lists
on each visit were screened for GDMT medication classes, and the following were considered on
GDMT: patients who were on each of the three classes of medications, and patients who were
African-American and not on ACEI, ARB, ARNI, but were on hydralazine and nitrate. If these
conditions were not met, patients were considered not on GDMT at those visits. Additionally,
rates of harmful medication (i.e., ibuprofen) prescriptions were calculated as well as the number
of clinic visits for each type, before and after pharmacist integration. SEE APPENDIX FOR
GDMT MEDS CRITERIA.
Data Analysis
As indirect effects on GDMT compliance could occur in the HF clinic with pharmacists
available for provider consults, visits were coded into the following three categories: 1) general
cardiology clinic visit; 2) HF clinic visit (where pharmacist installed); 3) pharmacist visit (in HF
clinic).
The number of patients with GDMT compliant prescriptions were estimated (as best
linear unbiased predictions) separately for the general cardiology clinic, HF clinic, and HF clinic
with a pharmacist. This same approach was used to estimate rates for harmful medication
prescriptions and compliance for three medications comprising GDMT. Calculations were
conducted separately for pre-integration and post-integration periods. Pairwise comparisons
between estimates by visit type were conducted (general cardiology vs HF clinic, general
cardiology vs HF clinic with pharmacist, HF clinic vs HF clinic with pharmacist).
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Due to the nested structure of the clinic visits within patient, a multilevel model was
tested. These models permit predictors to vary at more than one level (patient, clinic visit) and
account for non-independent (or correlated) observations. GDMT compliance was a
dichotomous variable; hence, parameters were estimated using a logistic generalized linear
mixed models (GLMM). Predictors entered in the model included: integration phase (pre/post),
study group (general cardiology visits, HF clinic visits, and pharmacist visits).
The number of general cardiology clinic visits, HF clinic visits, and pharmacist visits
were counted for pre-integration and post-integration time periods. Paired t-tests were used to
compare number of clinic visits between pre- and post-integration for general cardiology clinic
visits and HF clinic visits, separately. Patients that had at least one visit in the general cardiology
clinic were included in analysis comparing number of general cardiology visits between pre- and
post-integration. Similarly, patients had to have one HF clinic visit to be in included for
comparison of number of HF clinic visits. As a supplementary analysis, a test of independence
between GDMT compliance and provider type (NPs and physicians) was calculated (in general
cardiology clinics only).

RESULTS
The sample contained 754 unique patients that were about 65% male and 92.0% White.
Sample demographics and comorbidities are shown in Table 1.
GDMT compliance
The average number of clinic visits per patient was 2.67 (SD=1.86, median=2, range=1,
11). Of the total clinic visits during the study timeframe, 52.76% (1062/2013) occurred prior to
the pharmacist integration and 47.24% (951/2013) occurred after the pharmacist intervention.
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Table 1. Characteristics of the sample based on the first encounter that appeared for each unique
patient in the data set
Characteristics of unique patients who had encounter(s) included in the study (N=754)
Age mean (SD), range
73.8 (11.3), 34-89+
Gender n (%)
Male 488 (64.7)
Female 266 (35.3)
Ethnicity n (%)
Not Hispanic or Latino 738 (97.9)
Hispanic or Latino 5 (0.7)
No information 11 (1.4)
Race n (%)
White or Caucasian 694 (92.0)
Black or African American 45 (6.0)
Asian 2 (0.3)
Burmese 1 (0.1)
Native Hawaiian or Pacific Islander 1 (0.1)
No information 11 (1.4)
Comorbidities n (%)*
Hypertension 548 (72.7)
Diabetes 323 (42.8)
Coronary artery disease 448 (59.4)
Atrial Fibrillation 277 (36.7)
EF value mean (SD), range
29 (7.1), 5-39
*percent total equals more than 100 because people are counted in more than one group

Estimated posterior modes of GDMT compliance for post-integration period by visit type
are shown in Table 2. Pharmacist visits had a significantly higher rate of GDMT compliance and
significantly lower rate of harmful medication prescriptions than general cardiology visits
(p<.05). There was a significant difference in GDMT compliance between the HF clinic and the
general cardiology clinic after the integration of pharmacists (p<.05), but no significant
difference prior. There were no significant differences between pharmacist visits and HF clinic
visits in prescriptions for ARB, ACE, ARNI; MRA; and beta blockers. As shown in Table 3,
rates of GDMT compliance did not change in the general cardiology clinic or HF clinic from preto post-integration period.
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Table 2. Posterior modes of GDMT compliance and harmful medication prescriptions for preintervention and post-intervention by visit type
Time period

General
Cardiology
clinic

HF clinic

Pharmacist visits

Pre-intervention
(n=1062)
GDMT compliance
.25a
.31a
a
a
ACEI, ARB, or ARNI
.64
.58
MRA
.45a
.58b
a
a
Betablocker
.93
.94
a
b
Harmful Medication
.16
.09
Post-intervention
(n=951)
GDMT compliance
.24a
.35b
.41b
ARB, ACE, or ARNI
.67a
.70a
.71a
a
b
MRA
.40
.56
.63b
Betablocker
.92a
.95a
.97a
a
b
Harmful Medication
.18
.07
.04b
Note: ARB=Angiotensin receptor blockers, ACE=angiotensin converting enzyme inhibitors.
Superscripts indicate results from pairwise comparisons between posterior modes: the same
superscript indicates no difference; different superscripts indicate a significant difference (p<.05)
between modes.
Table 3. Summary of results from logistic random effects model predicting GDMT compliance
from visit type and integration period (pre/post) (n=2013 visits)
Predictor
Intercept
Integration period (pre vs
post)
Visit type (general vs
pharmacist)
Visit type (heart failure vs
pharmacist)

Estimate

Standard Error

p-value

-0.53
0.15

0.32
0.15

.10
.30

-0.80

0.34

.02

-0.38

0.34

.27

During the pre-integration period, 741 general cardiology clinic visits and 321 HF clinic
visits occurred. During the post-integration period, 630 general cardiology clinic visits and 240
HF clinic visits occurred. As shown in Table 4, about 20% of patients had visits in the HF clinic
in the pre-integration and post-integration period; in contrast, nearly 60% had visits in general
cardiology clinics for the same time periods. During the post-integration period, pharmacists had
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81 visits with 71 patients. About 82% (58/71) of patients with a pharmacist visit had other HF
clinic visits during the post-integration period as well. For both general cardiology clinic and HF
clinic the number of visits per patient declined significantly from pre- to post-integration period
(t(661)= 2.69, p=.007 and t(247)=2.56, p=.01, respectively).

Table 4. Healthcare utilization frequencies by visit type and intervention period (n=754 patients)
Time period

General
Cardiology
clinic

HF clinic

Pre-integration, n(%)
0
312 (41.38)
1
251 (33.29)
2
122 (16.18)
3+
69 (9.15)
Post-integration, n(%)
0
326 (43.24)
1
289 (38.33)
2
87 (11.54)
3+
52 (6.90)
Note: IQR=interquartile range

Pharmacist
visits

Total visits

-595 (78.91)
73 (9.68)
42 (5.57)
44 (5.84)
606 (80.37)
90 (11.94)
35 (4.64)
23 (3.05)

251 (33.29)
226 (29.97)
133 (17.64)
144 (19.10)
683 (90.58)
65 (8.62)
4 (0.53)
2 (0.27)

240 (31.83)
281 (37.27)
109 (14.46)
124 (16.45)

In a comparison of GDMT compliance between provider type, nurse practitioners (29%) and
physicians (27%) in general cardiology clinics had equivalent rates of GDMT compliance.

DISCUSSION
After the integration of pharmacists, the rate of GDMT compliance for HF clinic visits
became significantly higher than general cardiology clinic visits. Encounters where all three
classes of medications were prescribed for eligible patients among the general cardiology visits
was low. Low rates of MRA prescriptions may be a primary factor impacting overall GDMT
compliance. These findings align with research examining prescription of ACE/ARB/ARNI,
beta-blocker, and MRA therapy, where 27%, 33%, and 67% of eligible patients were not
prescribed these medications, respectively.[4]
During this study time period, the HF clinic workflow was undergoing adjustments, such
as when patients see the nurse practitioner and when they see the pharmacist, and for how long,
in an effort to make the best use of pharmacist input for improving GDMT compliance.
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Undocumented interactions, known as “curbside consultations” [9] that occurred between the
nurse practitioners and pharmacists in the HF clinic may have influenced GDMT prescription
rates for the HF clinic visits, particularly as compared to the cardiology clinic in the postintegration phase.
One important finding that emerged during the data collection process was that
exceptions to GDMT prescription were not uniformly or consistently documented. The ability to
document GDMT exceptions, such as inability to prescribe appropriate therapy due to abnormal
lab values or abnormal vital signs, is an important consideration in assessing the overall GDMT
compliance of providers. In an electronic health record that does not allow for the documentation
of exceptions to GDMT in a discrete fashion, the provider who attempts to place their patient on
appropriate GDMT but is unable to prescribe all recommended therapies due to contraindications
appears noncompliant even though they may be prescribing appropriately for the patient
situation. Allowing prescribers to document discretely their prescribing decisions will more
accurately reflect the true story of provider GDMT compliance. EMR systems require enhanced
data governance to ensure standardization of documentation with prescribing medication. Efforts
to create templates or workflow changes should focus on systematically documenting and
recording decisions about medications at point of care.[10]
The ability to document and track GDMT is especially important as GDMT is continually
evolving with evidence research to determine optimal therapy. For example, at the time of this
study, guidelines did not include SGLT2s, a class of medications that has been added to the
guidelines since 2017.[11] While the parameters for GDMT for this study included patients who
were African-American and on hydralazine and isosorbide and not ACEI, ARB, or ARNI,
updated guidelines emphasize that ARNIs are preferred if possible. The combination of
hydralazine and isosorbide has been shown to be effective and is considered a key therapy
among African Americans. However, clinical trials for ARNIs and newer medications have
included very few African Americans, and newer, effective medications that show efficacy in
these clinical trials should still be prescribed for African Americans so as not to broaden the
disparity in treatment [11]. Black adults, among whom heart failure prevalence, hospitalization,
and mortality rates are proportionally higher than for other races.[12] Additionally, research
suggests that GDMT requires attention to the individual patients’ needs [5] and proper guideline
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and tracking of GDMT would help with monitoring status and GDMT-related decision making at
both the patient and population levels.
Study Limitations
The pharmacists were integrated in a busy cardiology practice, and the study lacks
standardized documentation of implementation procedures and changes in the workflow and
communication. Thus, we are unable to account for the potential impacts of these factors during
the transition to integration of pharmacists that may have influenced the results. This study was a
retrospective analysis of a large cardiology group within a Health System. The results of this
effort may not translate to other practice models. Also, the appropriateness of GDMT
prescription may not be accurately reflected due to lack of standardized documentation of
exceptions to GDMT or other EMR data quality issues; moreover, the rate of these exceptions
could vary between HF visits and general cardiology visits. Beta-blockers were included for
GDMT that are not GDMT beta-blockers (see APPENDIX).

CONCLUSION
Integrating a pharmacist into the clinic can help increase prescription of GDMT in the HF
clinic. Improved GDMT compliance was observed within both pharmacist-only visits and within
visits with other clinicians at the HF clinic wherein the pharmacist was embedded. Future studies
should focus on understanding what aspects of integration of pharmacists (individual patient
visits, location and placement of the pharmacist in the clinic, adjacence of pharmacist visits to
NP visits, and curbside consultations with NPs) helped improve GDMT compliance in the HF
clinic. Additionally, efforts should focus on improving documentation and tracking of GDMT to
reflect the methods, decision-making, and clinician engagement when prescribing GDMT.
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APPENDIX

Medications used for determining GDMT eligibility in the chart review:

ACE

ARB

Hydralazine

Nitrate

benazepril (Lotensin)

candesartan (Atacand)

apresoline
(Hydralazine)

capozide
(Captopril/HCTZ)
captopril (Capoten)
enalapril (Vasotec)
fosinopril (Monopril)
lisinopril (Zestoretic)
lotensin (Benazepril)
moexipril (Univasc)
monopril (Fosinopril)
perindopril (Aceon)
prinzide
(Lisinopril/HCTZ)
quinapril (Accupril)
ramipril (Altace)
trandolapril (Mavik)
uniretic
(Moexipril/HCTZ)
vaseretic
(Enalapril/HCTZ)

irbesartan (Avapro)

hydra-zide
isosorbine mononitrate
(Hydralazine/HCTZ) (Imdur)

olmesartan medoxomil (Benicar)
losartan (Cozaar)
valsartan (Diovan)
azilsartan medoxomil (Edarbi)
telmisartan (Micardis)
valsartan (prexxartan)
eprosartan mesylate (Teveten)
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isosorbide dinitrate
(Isordil)

Entresto
(ARB/Angiotensin
II)
sacubitrol/valsartan
(Entresto)

MRA
eplerenone (Inspra)
spironolactone (Aldactone)

Beta Blocker*

digox

amlodipine (Norvasc)
diltiazem (Cardizem, Tiazac,
Dilacor)
felodipine (Plendil)

Nonsteroidal antiinflammatory
NSAIDs (harmful)
diclofenac (Voltaren)
etodolac (Lodine,
Lodine XL)
fenoprofen (Nalfon)

digitek

isradipine (Dynacirc)

flurbiprofen (Ansaid)

lanoxin

nifedipine (Adalat, Procardia)

lanoxicaps

nicardipine (Cardene)

ibuprofen (Advil,
Motrin)
indomethacin (Indocin)

Digoxin
(harmful)*

acebutolol (Sectral)
atenolol (Tenormin)

digoxin
cardoxin

bisoprolol fumarate
(Zebeta)
metoprolol tartrate
(Lopressor)
metoprolol succinate
(Toprol XL)
carvedilol (Coreg or
Coreg CR)
esmolol (Brevibloc)
labetalol (Trandate)
nadolol (Corgard)

Calcium channel blockers
(harmful)

nimodipine (Nimotop)
nisoldipine (Sular)
verapamil (Calan, Verelan,
Isoptin)

ketoprofen (Orudis)
ketorolac (Toradol)
meclofenamate
(Meclomen)
nebivolol (Bystolic)
mefenamic acid
(Ponstel)
penbutolol (Levatol)
meloxicam (Mobic)
pindolol (Visken)
nabumetone (Relafen)
propranolol (Inderal)
naproxen (Aleve)
sotalol (Betapace)
oxaprozin (Daypro)
piroxicam (Feldene)
salsalate (Disalcid)
sulindac (Clinoril)
tolmetin (Tolectin)
*The beta blockers highlighted in yellow are not considered GDMT per current guidelines. Amlodipine is the only non-harmful
calcium channel blocker, and Digoxin is not currently considered harmful and should not have been included.
(https://www.jacc.org/doi/pdf/10.1016/j.jacc.2017.11.025?_ga=2.184910889.1400773485.1531464937-823548432.1529040707)
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